HCA
VRTX icon

Heck Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Heck Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18
Closed -$7.25K – 770
2024
Q4 		$7.25K Buy
+18
New +$8.34K ﹤0.01% 555

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Heck Capital Advisors's VRTX Position: Q1 2025 in Review

Heck Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 18 shares — an estimated $7.25K sold.

Heck Capital Advisors first reported a position in VRTX in Q4 2024 and held it in 1 quarter. The position peaked at $7.25K in Q4 2024. 1,616 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Heck Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 18 Vertex Pharmaceuticals shares in Q1 2025, an estimated $7.25K.
  • Heck Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's Vertex Pharmaceuticals position peaked at $7.25K in Q4 2024.
  • 1,616 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.